Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diabetes: statins, fibrates, or both?

M Farnier1, S Picard

  • 1Point Medical, Rond-Point de la Nation, Dijon, F-21000, France. mfarnier@ipac.fr

Current Atherosclerosis Reports
|December 21, 2000
PubMed
Summary

Diabetic dyslipidemia significantly increases cardiovascular disease risk in type 2 diabetes patients. Management is challenging, often requiring statin or fibrate monotherapy, potentially followed by combination therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Practical implementation of automated insulin delivery systems in 2025: A French position statement update.

Diabetes & metabolism·2025
Same author

Determination of the lipid content of organic waste using time-domain nuclear magnetic resonance.

Waste management (New York, N.Y.)·2021
Same author

Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study.

Diabetes & metabolism·2021
Same author

Practical implementation of automated closed-loop insulin delivery: A French position statement.

Diabetes & metabolism·2020
Same author

Use of fermentation processes for improving the dissolution of phosphorus and its recovery from waste activated sludge.

Environmental technology·2020
Same author

Type 2 diabetes: Why should diabetologists and cardiologists work more closely together?

Diabetes & metabolism·2019

Area of Science:

  • Endocrinology
  • Cardiology
  • Metabolic Disorders

Background:

  • Cardiovascular disease (CVD) is the primary cause of death in type 2 diabetes (T2D) patients.
  • Diabetic dyslipidemia, characterized by elevated triglycerides, low high-density lipoprotein cholesterol (HDL-C), and normal or mildly elevated low-density lipoprotein cholesterol (LDL-C), is a major contributor to atherosclerosis in T2D.
  • Effective management strategies for diabetic dyslipidemia are hindered by a lack of diabetes-specific clinical trials.

Purpose of the Study:

  • To review the role of dyslipidemia in the pathogenesis of atherosclerosis in type 2 diabetes.
  • To discuss current challenges and strategies in managing diabetic dyslipidemia.
  • To outline therapeutic approaches for lipid management in diabetic patients.

Main Methods:

  • Review of existing literature, including post hoc analyses of major intervention trials and specific trials on diabetic patient cohorts.
  • Analysis of lipid profiles characteristic of diabetic dyslipidemia.
  • Evaluation of therapeutic options including lifestyle changes, monotherapy (statins, fibrates), and combination therapy.

Main Results:

  • Diabetic dyslipidemia is a critical factor in atherosclerosis development in type 2 diabetes.
  • Current treatment strategies rely on limited data, necessitating careful patient selection and monitoring.
  • Monotherapy with statins or fibrates is recommended initially, with combination therapy considered if lipid targets are unmet.

Conclusions:

  • Management of diabetic dyslipidemia requires a tailored approach due to unique lipid profiles and limited specific evidence.
  • Lifestyle modifications are foundational, followed by targeted pharmacotherapy.
  • Close monitoring for efficacy and adverse effects is crucial during monotherapy and combination therapy for diabetic dyslipidemia.

Related Experiment Videos